Authors

  • Boltayeva G.Sh., Abdumalikova M.D., Azzamova Sh.U., Raxmatillayev B.B.

Keywords:

pnevmokokk infektsiyasi, Streptococcus pneumoniae, kon’yugat pnevmokokk vaksinasi, polisaxarid pnevmokokk vaksinasi, vaksina samaradorligi, invaziv pnevmokokk kasalligi, profilaktika, serotip almashinuvi, nazofaringeal tashuvchilik.

References

1. Anglemyer, A., et al. (2024). The impact of pneumococcal serotype replacement on the incidence of invasive pneumococcal disease. The Lancet Regional Health – Western Pacific.

2. Bonten, M. J. M., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van Werkhoven, C. H., van Deursen, A. M. M., Sanders, E. A. M., Verheij, T. J. M., Patton, M., McDonough, A., Moradoghli-Haftvani, A., Smith, H., Mellelieu, T., Pride, M. W., Crowther, G., Schmoele-Thoma, B., Scott, D. A.,... Grobbee, D. E. (2015). Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. The New England Journal of Medicine, 372(12), 1114–1125. https://doi.org/10.1056/NEJM oa1408544

3. Centers for Disease Control and Prevention. (2026). Pneumococcal vaccine recommendations. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html

4. Kobayashi, M., Farrar, J. L., Gierke, R., Leidner, A. J., Campos-Outcalt, D., Morgan, R. L., Long, S. S., Talbot, H. K., Poehling, K. A., & Pilishvili, T. (2025). Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. Morbidity and Mortality Weekly Report, 74(1), 1–8.

5. Kobayashi, M., Leidner, A. J., Gierke, R., Farrar, J. L., Morgan, R. L., Campos-Outcalt, D., Poehling, K. A., Long, S. S., Talbot, H. K., & Pilishvili, T. (2023). Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Morbidity and Mortality Weekly Report Recommendations and Reports, 72(3), 1–39.

6. World Health Organization. (2019). Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Weekly Epidemiological Record, 94(8), 85–104.

7. World Health Organization. (2025). WHO position paper: Pneumococcal conjugate vaccines in infants and children aged <5 years – September 2025. Weekly Epidemiological Record.

8. World Health Organization. (2025). Pneumococcal conjugate 3rd dose (PCV3) immunization coverage among 1-year-olds (%). WHO Data.

9. World Health Organization. (2025). Pneumococcal vaccination coverage. WHO Immunization Data Portal. https://immunizationdata.who.int/global/wiise-detail-page/pneumococcal-vaccination-coverage

10. Wagner, G., Gartlehner, G., Thaler, K., Ledinger, D., Feyertag, J., Klerings, I., Saif-Ur-Rahman, K. M., Devane, D., Olsson, K., Adel Ali, K., Vygen-Bonnet, S., Salo, H., Zavadska, D., Grgic Vitek, M., Oona, M., Cunney, R., Tuerlinckx, D., Kristensen Lomholt, F., & Sommer, I. (2024). Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine: A systematic review and meta-analysis. NPJ Vaccines. https://www.nature.com/articles/s41 541-024-01048-y

11. Bennett, J. C., et al. (2025). Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages: The PSERENADE project, a global surveillance analysis. The Lancet Infectious Diseases.

12. Peng R, et al. Effectiveness and impact of 7- and 13-valent pneumococcal conjugate vaccines: systematic literature review and meta-analysis. Expert Rev Vaccines. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12530490/

13. Prunas, O., va boshq. (2024). Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries.

14. Centers for Disease Control and Prevention. (2026). Summary of risk-based pneumococcal vaccination recommendations. https://www.cdc.gov/pneumococcal/hcp/ vaccine-recommendations/risk-indications.html

15. Chang, C. Y., et al. (2025). Effectiveness of vaccine dosing schedules for pneumococcal conjugate vaccines against vaccine-type invasive pneumococcal disease in children: A systematic review and meta-analysis. IJID Regions.

16. Choi, Y. H., Bertran, M., Litt, D. J., Ladhani, S. N., & Miller, E. (2024). Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: A modelling study. The Lancet Public Health.

17. Essink, B., Sabharwal, C., Cannon, K., Frenck, R., Lal, H., Xu, X., Sundaraiyer, V., Peng, Y., Koury, K., Pride, M. W., & Gruber, W. C. (2022). Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged 18 years and older. Clinical Infectious Diseases, 75(3), 390–398. https://doi.org/10.1093/cid/ciab990

18. Farrar, J. L., Childs, L., Ouattara, M., Akhter, F., Britton, A., Pilishvili, T., & Kobayashi, M. (2023). Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults. Pathogens, 12(5), 732. https://doi.org/10.3390/pathogens12050732

19. Kobayashi, M., Farrar, J. L., Gierke, R., Leidner, A. J., Campos-Outcalt, D., Morgan, R. L., Long, S. S., Talbot, H. K., Poehling, K. A., & Pilishvili, T. (2025). Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. Morbidity and Mortality Weekly Report, 74(1), 1–8.

20. Kobayashi, M., Leidner, A. J., Gierke, R., Farrar, J. L., Morgan, R. L., Campos-Outcalt, D., Poehling, K. A., Long, S. S., Talbot, H. K., & Pilishvili, T. (2023). Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Morbidity and Mortality Weekly Report: Recommendations and Reports, 72(3), 1–39.

21. Quesada, M. G., et al. (2025). Serotype distribution of remaining invasive pneumococcal disease after long-term use of ten-valent or 13-valent pneumococcal conjugate vaccines: The PSERENADE project. The Lancet Infectious Diseases.

22. Wagner, G., Gartlehner, G., Thaler, K., Ledinger, D., Feyertag, J., Klerings, I., Saif-Ur-Rahman, K. M., Devane, D., Olsson, K., Ali, K. A., Vygen-Bonnet, S., Salo, H., Zavadska, D., Grgic Vitek, M., Oona, M., Cunney, R., Tuerlinckx, D., Lomholt, F. K., & Sommer, I. (2024). Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine: A systematic review and meta-analysis. NPJ Vaccines, 9, Article 235.

23. Agzamova Sh.A, Mirraximova M.X., Bolalarda pnevmoniya: O‘quv qo‘llanma. Toshkent tibbiyot akademiyasi. (2023).

24. Bender, R. G., Ikuta, K. S., Blok, L. M., Knoll, M. D., Dwyer-Lindgren, L., Mulholland, K.,... GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. (2024). Global, regional, and national incidence and mortality of lower respiratory infections and aetiologies from 1990 to 2021: A systematic analysis from the Global Burden of Disease Study 2021. The Lancet Infectious Diseases, 24(8). doi: 10.1016/S1473-3099 (24) 00176-2

25. CDC. Pneumococcal vaccination: Information for health care providers. https:// www.cdc.gov/vaccines/hcp/by-disease/ pneumo.html

26. Centers for Disease Control and Prevention. (2026, February 25). Clinical overview of pneumococcal disease.

27. Dai, Q., va boshq. (2025). Efficacy, immunogenicity, and safety of pneumococcal conjugate vaccine in children: a systematic review and meta-analysis. Frontiers in Pediatrics.

28. Karimdjanov, I.A.; Shomansurova, E.A; Madraximov, P.М. Pnevmokokk infeksiyasiga qarshi emlangan va emlanmagan erta yoshli bolalarda pnevmoniya kasalligini davolashga zamonaviy yondashuvlar. Педиатрия научно-практический журнал (2023), p333-343

29. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2025). Shifoxonadan tashqari pnevmoniya: Tashxislash va davolash bo‘yicha milliy klinik protokol.

30. O‘zbekiston Respublikasi Vazirlar Mahkamasi. (2021, 30-sentabr). Aholini majburiy emlash tizimini joriy etish chora-tadbirlari to‘g‘risida. https://lex.uz/docs/-5524039

31. Ouldali, N., va boshq. (2021). Invasive pneumococcal disease incidence in children and adults in France before and after the pneumococcal conjugate vaccine era. The Lancet Infectious Diseases.

32. Oʻzbekiston Respublikasi Sogʻliqni saqlash vazirligi. (2024). “Shifoxonadan tashqari pnevmoniya” nozologiya boʻyicha milliy klinik protokol. Akademik Shakir Alimov nomidagi ixtisoslashtirilgan ftiziatriya va pulmonologiya ilmiy-amaliy tibbiyot markazi.

33. Rahmonov, R. N. (2023). Oʻzbekiston respublikasida profilaktik emlash tizimidagi islohotlarning afzalliklari. In J. A. Rizaev (Ed.), 77-y xalqaro ilmiy-amaliy konferensiya “Fundamental, amaliy tibbiyot va farmatsiya yutuqlari” materiallari toʻplami (p. 131). Samarqand davlat tibbiyot universiteti.

34. Wagner G, et al. Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis. npj Vaccines. 2024. https://www.nature.com/articles/s41541-024-01048-y

35. Weaver J, et al. Incidence of pneumococcal disease in children in Germany after the introduction of pneumococcal conjugate vaccination. BMC Pediatrics. 2024. https:// bmcpediatr.biomedcentral.com/articles/10. 1186/s12887-024-05003-7